Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 3
1975 8
1976 7
1977 6
1978 2
1979 7
1980 3
1981 1
1982 3
1983 1
1984 2
1985 5
1986 7
1987 8
1988 4
1989 4
1990 3
1991 4
1992 4
1993 3
1994 3
1995 5
1996 10
1997 7
1998 5
1999 7
2000 9
2001 10
2002 7
2003 9
2004 8
2005 9
2006 10
2007 8
2008 11
2009 12
2010 16
2011 13
2012 12
2013 18
2014 19
2015 16
2016 16
2017 14
2018 15
2019 18
2020 15
2021 21
2022 20
2023 8
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Results by year

Filters applied: . Clear all
Page 1
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y. Janes MR, et al. Among authors: lorenzi mv. Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006. Cell. 2018. PMID: 29373830 Free article.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Among authors: lorenzi mv. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, Sendecki J, Beqiri M, Millar HJ, Packman K, Lorenzi MV, Laquerre S, Moores SL. Vijayaraghavan S, et al. Among authors: lorenzi mv. Mol Cancer Ther. 2020 Oct;19(10):2044-2056. doi: 10.1158/1535-7163.MCT-20-0071. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747419
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM. Moores SL, et al. Among authors: lorenzi mv. Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23. Cancer Res. 2016. PMID: 27216193
Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Dabbous O, et al. Among authors: lorenzi m. Adv Ther. 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11. Adv Ther. 2019. PMID: 31512141 Free PMC article. No abstract available.
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Brehmer D, Beke L, Wu T, Millar HJ, Moy C, Sun W, Mannens G, Pande V, Boeckx A, van Heerde E, Nys T, Gustin EM, Verbist B, Zhou L, Fan Y, Bhargava V, Safabakhsh P, Vinken P, Verhulst T, Gilbert A, Rai S, Graubert TA, Pastore F, Fiore D, Gu J, Johnson A, Philippar U, Morschhäuser B, Walker D, De Lange D, Keersmaekers V, Viellevoye M, Diels G, Schepens W, Thuring JW, Meerpoel L, Packman K, Lorenzi MV, Laquerre S. Brehmer D, et al. Among authors: lorenzi mv. Mol Cancer Ther. 2021 Dec;20(12):2317-2328. doi: 10.1158/1535-7163.MCT-21-0367. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583982 Free PMC article.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Among authors: lorenzi mv. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788
The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans.
Jyväkorpi SK, Ramel A, Strandberg TE, Piotrowicz K, Błaszczyk-Bębenek E, Urtamo A, Rempe HM, Geirsdóttir Ó, Vágnerová T, Billot M, Larreur A, Savera G, Soriano G, Picauron C, Tagliaferri S, Sanchez-Puelles C, Cadenas VS, Perl A, Tirrel L, Öhman H, Weling-Scheepers C, Ambrosi S, Costantini A, Pavelková K, Klimkova M, Freiberger E, Jonsson PV, Marzetti E, Pitkälä KH, Landi F, Calvani R; SPRINTT consortium. Jyväkorpi SK, et al. Eur Geriatr Med. 2021 Apr;12(2):303-312. doi: 10.1007/s41999-020-00438-4. Epub 2021 Feb 13. Eur Geriatr Med. 2021. PMID: 33583000 Free PMC article. Clinical Trial.
Integration of Multimodal Data.
Lorenzi M, Deprez M, Balelli I, Aguila AL, Altmann A. Lorenzi M, et al. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 19. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 19. PMID: 37988505 Free Books & Documents. Review.
419 results